Ruben Pio

Has grant

Professor

Universidad de Navarra

Spain

Research Interests

Explore related searches

Professors in Spain Professors in Immunology Immunology professors in Spain

Contact this professor

ORCID

Google Scholar

Academic Page

About

Professor Ruben Pio is a faculty member at Universidad de Navarra, Spain. His research focuses on cancer immunotherapy, particularly in the areas of DNA damage repair mechanisms, epigenetic regulation, and the role of the complement system in oncology. He has published recent articles exploring the efficacy of various therapeutic approaches in treating different cancer types, including triple-negative breast cancer and non-small cell lung cancer.

Recent Grants

Grant: Close

INGENIO (INtegrative GENomic, digital Imaging and clinical information towars Precision Oncology Optimization)

Open Date: 2022-01-01

Close Date: 2025-01-01

Grant: Close

Caloric restriction as a tool to enhance the efficacy and minimize the toxicity of immunotherapy against lung cancer

Open Date: 2022-01-01

Close Date: 2024-01-01

Grant: Close

New biomarkers for a personalized determination of lung cancer risk in low-dose CT screening protocols: development and validation of high-sensitivity protein signatures in combination with radiomic analysis

Open Date: 2022-01-01

Close Date: 2024-01-01

Grant: Close

Modulation of the complement system to improve antitumor activity and decrease side effects of immunotherapy against lung cancer

Open Date: 2021-01-01

Close Date: 2023-01-01

Grant: Close

Discovering immune therapeutic vulnerabilities in KRAS/STK11-mutant lung adenocarcinomas

Open Date: 2020-01-01

Close Date: 2022-01-01

Ruben Pio

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (20)

Co-targeting of epigenetic regulators and BCL-XL improves efficacy of immune checkpoint blockade therapy in multiple solid tumors.

Dual ENPP1/ATM depletion blunts DNA damage repair boosting radioimmune efficacy to abrogate triple-negative breast cancer.

The C5a/C5aR1 Axis Promotes Migration of Tolerogenic Dendritic Cells to Lymph Nodes, Impairing the Anticancer Immune Response.

Whole exome sequencing and machine learning germline analysis of individuals presenting with extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma

The complement system in clinical oncology: Applications, limitations and challenges.

G9a/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1.

Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.

Fasting and fasting-mimicking conditions in the cancer immunotherapy era.

Elevated expression of complement factor I in lung cancer cells associates with shorter survival-Potentially via non-canonical mechanism.

Plasma fractalkine contributes to systemic myeloid diversity and <scp>PD‐L1</scp>/<scp>PD</scp>‐1 blockade in lung cancer

Tumor ENPP1(CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer.

Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis.

Two alternative cell line models for the study of multiorganic metastasis and immunotherapy in Lung Squamous Cell Carcinoma.

Persistence of High Levels of Serum Complement C5a in Severe COVID-19 Cases After Hospital Discharge.

The Complement System in Ovarian Cancer: An Underexplored Old Path

A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer

Molecular biomarkers in early stage lung cancer

SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

Surgical Outcomes in a Lung Cancer-Screening Program Using Low Dose Computed Tomography,Resultados quirúrgicos de un programa de cribado de cáncer de pulmón utilizando tomografía computarizada de baja dosis

Whole exome sequencing characterization of individuals presenting extreme phenotypes of high and low risk of developing tobacco-induced lung adenocarcinoma

Collaborators (14)

Marta Santisteban

Ana Patiño-García

Diego Serrano

marisol gonzalez-huarriz

Victor Segura

Jose Maria Lopez-Picazo

Eloisa Jantus Lewintre

Maria Jose Pajares

Graziella Bosco

Cristina Bértolo

Jose Yuste

Nerea Varo

Juan Berto

Daniel Ajona

How do I reach out?

Meet Kite AI